Proteome Systems Ltd and US-based Egenix Inc. to Develop Semen-based Test for Prostate Cancer

Proteome Systems Ltd (ASX:PXL) today announced the signing of an agreement with the New York based biotechnology company, Egenix Inc to co-develop a semen-based diagnostic kit for prostate cancer based on the known proprietary Human Carcinoma Antigen (HCA)

Source: Proteome Systems